Posizioni attive di Karl Richard Gibson
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Ixchelsis Ltd.
 Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | 27/07/2011 | - |
| Fondatore | 27/07/2011 | - | |
| Sandexis LLP | Fondatore | - | - |
Storia della carriera di Karl Richard Gibson
Formazione di Karl Richard Gibson
| University of Cambridge | Doctorate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 4 |
Posizioni
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Health Technology |
| Sandexis LLP |
- Borsa valori
- Insiders
- Karl Richard Gibson
- Esperienza
